Aegon to Sell U.K. Unit to Standard Life in $2.7 Billion Deal

Aegon said it has struck a deal to sell its U.K. insurance and pensions business to Standard Life for a total consideration of £2.0 billion, equivalent to about $2.7 billion. The transaction is structured as a mix of cash and equity, leaving Aegon with a significant stake in the enlarged Standard Life group as part of the consideration.

The sale follows Aegon’s strategic review announced in 2025 that signalled a pivot toward the U.S. market and an eventual rebranding to Transamerica. Company statements indicate the deal is expected to close subject to regulatory approvals and customary conditions, with completion targeted toward the end of the year. Aegon has framed the disposal as part of portfolio reshaping to concentrate on life insurance and retirement solutions in the United States.

Market implications are material for the U.K. retirement savings sector: the combination of Aegon’s U.K. book with Standard Life’s existing assets would create one of the largest providers of retirement savings and income in the market, expanding scale and distribution. For Aegon, the transaction trims its European footprint and adjusts future free cash flow contribution assumptions tied to the U.K. block. Early market reaction will hinge on integration details and the timing of regulatory sign-off.

In a broader context, the deal is consistent with Aegon’s ongoing exits from certain European insurance operations in recent years and its intention to operate under the Transamerica name once U.S. repositioning is complete. Regulators in the U.K. and competition authorities will review the transaction, and any conditions imposed could affect the timetable and economics. The sale also reflects wider sector trends of consolidation in mature pension markets.

Analysts say the move should improve Aegon’s capital allocation flexibility and sharpen its strategic focus, while Standard Life faces execution risks around integration and realizing cost synergies. Investors will watch forthcoming regulatory filings, the exact mix of cash and equity consideration, and near-term guidance from both groups to assess the financial and operational impact. Subsequent trading in Aegon and Standard Life equity is likely to reflect clarity on those points.